SFG SCIENCES Welcomes Steve Engen and Ayako Kaiho to Key Leadership Roles
Yokohama, Japan – April 8, 2024
SFG SCIENCES, a clinical stage biopharmaceutical company, is pleased to announce the appointment of Steve Engen as a Board Member and Ayako Kaiho as an Auditor.
Steve Engen brings a wealth of experience in strategic management and business development to his new role as a Board Member at SFG SCIENCES. He spent over 25 years with senior executive level operating and transaction experience in the biopharmaceutical industry, with expertise in Japanese/Asian markets. In 1998, Steve established Mundipharma Japan and was president for nine years. From 2007, Steve served as CEO of Solasia Pharma, a cancer-focused development stage company. From 2012, he headed the Japanese operations of Shire Pharmaceuticals until 2014 when he established his own biopharma consultancy. After moving to Seattle in 2019, Steve established Renexes LLP to continue to facilitate transactions between Japanese and western biopharmaceutical companies. With a proven track record of driving growth and innovation, Steve’s expertise will be instrumental in guiding the company’s strategic direction.
“I am honored to join SFG SCIENCES and contribute to its mission of advancing healthcare solutions,” said Steve. “SFG SCIENCES is an example of innovation occurring in Japan biotech, and I look forward to collaborating with the talented team at SFG SCIENCES to bring novel therapies to patients and their families.”
Ayako Kaiho’s appointment as an Auditor further strengthens SFG SCIENCES’ commitment to transparency and accountability. Having over thirty years of experiences in management and governance as a founder, a member of operating management team or a consultant to hospital, consumer product and financial industries, she has gained confidence in building and helping new business and securing the clarity and sustainability of operation. Her working experiences in the US also contribute to those projects with global talents of diversified expertise and background. Most recently Ms. Kaiho has served as the board member of Kato Sangyo, a prime market listed food wholesaler. With her strong background in management and compliance, Ayako will play a key role in ensuring the integrity of the company’s financial and operation reporting processes.
“I am excited to join SFG SCIENCES as an Auditor,” said Ms. Kaiho. “I am committed to upholding the highest standards of corporate governance and contributing to the company’s continued success.”
“We are delighted to welcome both Steve Engen and Ayako Kaiho to our leadership team,” said Hiroshi Nagabukuro, CEO of SFG SCIENCES. “Their diverse expertise and strategic insights will be invaluable as we continue to drive innovation and deliver exceptional results for our clients.”
About SFG SCIENCES:
SFG SCIENCES is a clinical stage biopharmaceutical company. With a focus on innovation and collaboration, SFG SCIENCES is dedicated to advancing healthcare solutions that improve patients’ lives globally.
For media inquiries, please contact: